Nuvectis Pharma, Inc.

NVCT

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001875558


None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $31.7M
Warnings	thin data not computable: degenerate inputs, distress, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Feb 11, 2026 262 days before the rescan; latest periodic filing 10-Q received Aug 4, 2026
Last close	$18.38 2026-10-30; market equity $598.8M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 11, 2026

We are a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. We seek to develop drug candidates in the precision medicine space, and our processes for selection and clinical development of drug candidates are based on scientific data into cancer-promoting factors, as well as our understanding of the clinical landscape and regulatory requirements. We were incorporated in July 2020 under the laws of the State of Delaware under the name Centry Pharma, Inc., and changed our name to Nuvectis Pharma, Inc. in July 2021.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 10.0						
Gross profitability	not computable	32.4%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(41.5%)	(6.6%)	10.0	803	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 65.0					
Twelve-month failure probability	not computable	0.07%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(10.83)	(0.35)	64.1	748	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	2.38x	2.92x	65.9	829	2025-12-31
Growth and financing, sleeve percentile 40.3					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 0					
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 0					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	15.8%	2.2%	25.6	696	2025-12-31
Net share issuance, one year	13.3%	2.5%	55.1	631	2026-02-06

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	5 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-30 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	277.6%	7.3%	98
Distance from 52-week high	(35.2%)	(28.7%)	41
EBIT to enterprise value	not computable	(1.4%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	0.02	0.28	14
Sales to price	not computable	0.30	
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	1.12	(0.14)	98

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$22.2M
Operating cash flow, four quarters	-$19.5M
Months of runway	13.6
Days since last periodic filing	88 (10-Q received Aug 4, 2026)
Median daily dollar volume, 63 sessions	$3.6M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$26.4M	2025-12-31	2026-02-11	10-K	26-013044
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$16.0M	2025-12-31	2026-02-11	10-K	26-013044
3	assets	us-gaap:Assets	$31.7M	2025-12-31	2026-02-11	10-K	26-013044
4	assets	us-gaap:Assets	$18.6M	2024-12-31	2026-02-11	10-K	26-013044
5	current assets	us-gaap:AssetsCurrent	$31.7M	2025-12-31	2026-02-11	10-K	26-013044
6	current liabilities	us-gaap:LiabilitiesCurrent	$13.3M	2025-12-31	2026-02-11	10-K	26-013044
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$99.7M	2025-12-31	2026-02-11	10-K	26-013044
8	operating income	us-gaap:OperatingIncomeLoss	-$27.6M	2025-12-31	2026-02-11	10-K	26-013044
9	book equity	us-gaap:StockholdersEquity	$18.4M	2025-12-31	2026-02-11	10-K	26-013044
10	liabilities	us-gaap:Liabilities	$13.3M	2025-12-31	2026-02-11	10-K	26-013044
11	assets	us-gaap:Assets	$19.2M	2023-12-31	2025-02-25	10-K	25-001496
12	assets	us-gaap:Assets	$20.4M	2022-12-31	2024-03-05	10-K	24-002497
13	shares outstanding	dei:EntityCommonStockSharesOutstanding	26,491,702	2026-02-06	2026-02-11	10-K	26-013044
14	shares outstanding	dei:EntityCommonStockSharesOutstanding	23,391,499	2025-02-21	2025-02-25	10-K	25-001496

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.